Today: 30 June 2026
Lumentum stock price rebounds after Thursday slide as Form 144 sale notice hits tape
28 February 2026
2 mins read

Lumentum stock price rebounds after Thursday slide as Form 144 sale notice hits tape

New York, February 27, 2026, 17:59 EST — After-hours trade.

  • Lumentum bounced back to close out the week in positive territory, recovering from a steep decline just the day before.
  • The SEC just posted a new notice about an upcoming insider sale, stirring up more chatter.
  • Next week, investors will be looking for demand clues as management takes the stage at various conferences.

Lumentum Holdings Inc (LITE) finished Friday up 3.5% at $700.91. After hours, the stock barely moved, slipping just 0.03% to $700.70.

The stock’s action has suddenly become a bellwether for AI data-center demand in optical hardware. It’s rallied sharply over the past month, and with volatility in the wider market, upcoming management updates could swing the shares in a hurry.

The stock’s been anything but steady this week. On Wednesday, it finished at $723.39. Thursday saw a 6.4% drop. Come Friday, the price swung from $672.01 up to $720.10, with volume hitting roughly 8.9 million shares.

According to a Form 144 filed Friday, Morgan Stanley Smith Barney is planning to sell 5,302 shares of Lumentum, valued in total at about $3.66 million. The filing also noted that about 71.4 million Lumentum shares are currently outstanding.

Insiders file a Form 144 with the SEC to indicate plans to sell restricted or “control” stock as laid out in Rule 144. The filing doesn’t confirm an actual sale has taken place—it’s simply a heads-up, and the stock can be sold in portions over a period of time.

Lumentum’s management team has been making the rounds on the conference trail. They were lined up for the Susquehanna 15th Annual Technology Conference on Feb. 26, and are set to present at the Morgan Stanley Technology, Media & Telecom Conference on Monday, March 2.

Lumentum, back in early February, told investors it’s “only at the starting line” on two big growth initiatives—optical circuit switches and co-packaged optics. The company reported its optical-circuit-switch backlog had ballooned “well beyond $400 million” as demand ramped up. CEO Michael Hurlston added that Lumentum landed an “incremental multi-hundred-million-dollar” co-packaged optics order, slated for delivery in the first half of calendar 2027. Lumentum Investor Relations

Optical circuit switches push data around big data centers using light. Co-packaged optics, on the other hand, brings optical parts right up next to the compute and switch chips, which means more data can move using less power. With AI clusters expanding and networking equipment straining to keep up, both technologies are drawing fresh interest.

Within the broader sector, optical and networking stocks closed in positive territory. Coherent picked up 3.5%, while Ciena gained 2.2% on the session.

No lift from the wider market, either. On Friday, the S&P 500 slipped 0.4%, while the Nasdaq composite tumbled 0.9%. Inflation headlines and another round of jockeying between AI winners and laggards kept traders on edge.

Analyst targets have shifted as well. According to data from Fintel, published Wednesday on Nasdaq.com, Lumentum’s average price target for the next year sits at $565.29. The range stretches from $385.03 up to $945.00. Yet now that shares have climbed well past that average, any slip in orders or delivery could hit the stock faster.

The worry is that this could shift from a straightforward AI infrastructure play to a momentum-heavy trade—leaving the stock exposed to profit-taking, insider sale buzz, or any offhand cautious remark. Next week’s focus: specific updates, beginning with the Morgan Stanley event on March 2. Eyes will also be on the company’s investor briefing at OFC, set for March 17.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • HCW Biologics (HCWB) Back in Step with Nasdaq Bid Price Rule
    June 30, 2026, 9:25 AM EDT. HCW Biologics Inc. (Nasdaq: HCWB) is back in compliance with Nasdaq's minimum bid price rule, with the exchange's Hearings Panel signing off as of June 29, 2026. The panel said the company now meets Listing Rule 5550(a)(2) and will stay under a monitoring period until June 17, 2027. HCW Biologics plans a one-for-six reverse stock split on June 30, 2026, to stay compliant. The biotech works on fusion immunotherapeutics for chronic inflammation diseases like autoimmune disorders and cancer. Staying listed on Nasdaq supports its clinical and business push.
IonQ stock jumps nearly 22% after results; 2026 revenue outlook and SkyWater deal in focus
Previous Story

IonQ stock jumps nearly 22% after results; 2026 revenue outlook and SkyWater deal in focus

Why Is AI Not Perfect? Regulators Are Forcing Chatbots to Admit the Flaw
Next Story

Why Is AI Not Perfect? Regulators Are Forcing Chatbots to Admit the Flaw

Go toTop